

13 June 2019

NSX Announcement

STRATEGIC COOPERATION WITH PROFESSOR TAKUYA TSUNODA

Beroni Group Limited (NSX: BTG, OTCQX: BNIGF) (“Beroni Group” or the “Company”) have recently signed a strategic cooperation agreement with Professor Takuya Tsunoda to jointly develop immunotherapy and new drugs for cancer treatment.

Professor Takuya Tsunoda is a professor at the School of Medical Oncology at Showa University, Japan and is a leading pioneer in the field of cancer immunotherapy. At the signing ceremony, he said “There are four therapies for cancer – surgery, radiotherapy, chemotherapy and immunotherapy. The first three therapies target the cancer whereas immunotherapy target the immune system and not the cancer. Immunotherapy can effectively slow down the pathology and spread of cancer. With the rapid development of medical science, cancer will no longer be looked upon as a life-threatening disease but just a chronic disease.”

Beroni Group’s Chairman, Jacky Zhang said “We are very honoured to be able to cooperate with Professor Takuya Tsunoda. Professor Tsunoda has vast experience in the field of cancer immunotherapy and clinical care. We welcome him to our alliance of scientists who focus on precision medicine. This collaboration will enhance our Group’s core research and development capability and open up new paths for us in the use of immunotherapy for precise diagnosis and treatment of cancer. We hope to share and exchange our resources in scientific research, technology and talents with Professor Tsunoda’s team.”

For further information please contact:

Mr Jacky Zhang
Executive Chairman
Tel: +86 1851 6931 911
E: jacky.zhang@beronigroup.com

Mr Peter Wong
Executive Director and CFO
Tel: +61 423 727 580
E: peter.wong@beronigroup.com

About Beroni Group Limited (NSX:BTG) (OTCQX:BNIGF)

Beroni Group is an international biotechnological company listed on the National Stock Exchange of Australia and on the OTC markets in the U.S.A.. It currently has four core businesses - cell therapies, developing new anti-cancer drugs, e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases.

Beroni Group’s overall strategic goal is to become a world’s leading enterprise in the biotechnology, life sciences and environmental science industries.